A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2002
11/14/2002	US20020168631 Random gene unidirectional antisense library
11/14/2002	US20020168434 Cyclooxygenase inhibitor; anticancer agents, Alzheimer's disease, central nervous system disorders
11/14/2002	US20020168415 Biocompatible; culture product; anticancer agents
11/14/2002	US20020168411 Spill resistant pharmaceutical system
11/14/2002	US20020168388 Topical cosmetic composition
11/14/2002	US20020168385 Adeno-associated virus vector for boosting immunogenicity of cells
11/14/2002	US20020168375 Biosynthetic binding proteins for immuno-targeting
11/14/2002	US20020168366 Administering a binding agent capable of binding platelets binding platelets to the binding agent to form captured platelets, inducing activation of the captured platelets and forming a thrombus, which provides therapeutic benefit
11/14/2002	US20020168363 Integrin/adhesion antagonists
11/14/2002	US20020168358 Modulating the binding of the particular chemokines SLC (secondary lymphoid chemokine), and MIP-3b (macrophage inflammatory protein-3b), to immune system T-cells and dendritic cells to treat adverse inflammatory responses etc
11/14/2002	US20020168351 Fusion cells and cytokine compositions for treatment of disease
11/14/2002	US20020168349 A viral DNA construct encoding for a virus capable of replication in a human or animal tumor cell and causing death of such tumor cells
11/14/2002	US20020168347 Monocyte derived cells, in a purified form, presenting antigenic epitopes on their membranes after interioriztion and processing of an antigen-antibody complex, such epitope corresponding to proteolytic degradation product of antigen
11/14/2002	US20020168344 Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
11/14/2002	DE10122523A1 New 1,3-dihydroxybenzo-fused decalactone compounds, are cellular kinase inhibitors and hormone receptor inhibitors, useful as e.g. antitumor, anti-infective, antifungal and antiprotozoal drugs
11/14/2002	DE10121982A1 Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung Nanoparticles of protein with coupled apolipoprotein E to cross the blood-brain barrier and method for their preparation
11/14/2002	CA2453223A1 Selective anthranilamide pyridinamides as vegfr-2 and vegfr-3 inhibitors
11/14/2002	CA2449166A1 Combination therapy using anti-egfr antibodies and anti-hormonal agents
11/14/2002	CA2447360A1 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
11/14/2002	CA2447045A1 Method for treatment of tumors using nordihydroguaiaretic acid derivatives
11/14/2002	CA2446857A1 Reproductive cancer diagnosis and therapy
11/14/2002	CA2446810A1 Epidermal growth factor receptorantisense oligonucleotides
11/14/2002	CA2446788A1 Compositions and methods for the therapy and diagnosis of prostate cancer
11/14/2002	CA2446458A1 Toll/interleukin-1 receptor adaptor protein (tirap)
11/14/2002	CA2446437A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
11/14/2002	CA2446396A1 N-aroyl cyclic amines
11/14/2002	CA2446363A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	CA2446087A1 Recombinant tumor specific antibody and use thereof
11/14/2002	CA2446062A1 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof
11/14/2002	CA2446051A1 Phthalazine derivatives with angiogenesis inhibiting activity
11/14/2002	CA2446036A1 A method for transfection of rna using electrical pulses
11/14/2002	CA2445679A1 Benzazepinone alpha v integrin receptor antagonists
11/14/2002	CA2445065A1 Trimethyl lock based tetrapartate prodrugs
11/14/2002	CA2444531A1 Isoquinolinone derivatives as parp inhibitors
11/14/2002	CA2444013A1 Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof
11/14/2002	CA2435142A1 Kinases and phosphatases
11/14/2002	CA2385809A1 Alkylamide compounds
11/13/2002	EP1256586A1 Galectin recognized photosensitizers for photodynamic therapy
11/13/2002	EP1256578A1 Thiazole derivatives and their use as cdk inhibitors
11/13/2002	EP1256576A1 Fused imidazolium derivatives
11/13/2002	EP1256354A1 Methods for treating cancer
11/13/2002	EP1256351A1 Novel immune enhancing compositions
11/13/2002	EP1256344A1 Remedies for endothelin-induced diseases
11/13/2002	EP1256341A1 Cancer remedy comprising anthranilic acid derivative as active ingredient
11/13/2002	EP1255850A1 AMPLIFICATION OF $i(CYP24) AND USES THEREOF
11/13/2002	EP1255845A2 Modified cytokines for use in cancer therapy
11/13/2002	EP1255842A1 Larynx carcinoma-associated protein larcap-1
11/13/2002	EP1255837A2 Il-17 like molecules and uses thereof
11/13/2002	EP1255835A2 Polypeptides and nucleic acids encoding same
11/13/2002	EP1255834A2 Gtpase activating proteins
11/13/2002	EP1255833A2 Polypeptides and nucleic acids encoding same
11/13/2002	EP1255829A2 Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization
11/13/2002	EP1255828A2 Small oligonucleotides with anti-tumor activity
11/13/2002	EP1255819A2 Human kinases
11/13/2002	EP1255758A1 Apoptosis-inducing compounds
11/13/2002	EP1255756A1 Saccharin derivatives as orally active elastase inhibitors
11/13/2002	EP1255753A2 Prodigiosin-derivatives as neoplastic and anti-viral agents
11/13/2002	EP1255752A2 Pyrrole substituted 2-indolinone protein kinase inhibitors
11/13/2002	EP1255751A2 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors
11/13/2002	EP1255748A1 Beta-alanine derivatives and their use as receptor antagonists
11/13/2002	EP1255746A1 Oxy- and amino-substituted tetrahydrofuryl derivatives with antimour activity
11/13/2002	EP1255745A2 Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin iii
11/13/2002	EP1255744A1 Substituted phenylamidines medicaments containing said compounds and method for production thereof
11/13/2002	EP1255738A2 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
11/13/2002	EP1255733A1 Farnesyl transferase inhibitors
11/13/2002	EP1255732A1 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
11/13/2002	EP1255729A1 Preparation of nitrogen mustard derivatives
11/13/2002	EP1255725A2 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents
11/13/2002	EP1255566A2 Preparation of aqueous clear solution dosage forms with bile acids
11/13/2002	EP1255563A1 Composition of antigen and glycolipid adjuvant sublingual administration
11/13/2002	EP1255558A1 Uses of agonists and antagonists to modulate activity of tnf-related molecules
11/13/2002	EP1255554A2 Kidney-specific tumor vaccine directed against kidney tumor antigen g-250
11/13/2002	EP1255553A2 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers
11/13/2002	EP1255551A1 Use of paullone derivatives for making medicines
11/13/2002	EP1255542A1 Substituted amino acids as neutral sphingomyelinase inhibitors
11/13/2002	EP1255538A2 Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
11/13/2002	EP1255537A2 Farnesyl protein transferase inhibitors for treating breast cancer
11/13/2002	EP1255536A2 Indolinone derivatives for modulation of c-kit tyrosine protein kinase
11/13/2002	EP1183250A4 Semi-synthesis of paclitaxel using dialkyldichlorosilanes
11/13/2002	EP1140916B1 Heteroaryl-cyclic acetals
11/13/2002	EP1140200B1 Anthraquinone anticancer drugs
11/13/2002	EP1090006A4 Alkyl ether analogs of chlorins having an n-substituted imide ring
11/13/2002	EP1003536B1 Immunostimulatory and metastasis inhibiting fermented material from wheat germ
11/13/2002	EP0843557B1 Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein
11/13/2002	EP0697889B1 COMBINED TREATMENT OF IRON DEPLETION AND IgG ANTIBODY
11/13/2002	EP0650489B1 Rapamycin derivatives
11/13/2002	CN1379820A Lentiviral vectors for preparation of immunotherapeutical compositions
11/13/2002	CN1379816A Human G-protein coupled receptor
11/13/2002	CN1379814A Embryonic or stem-like cell lines produced by cross species nuclear transpcantation and methods for enhancing mebryonic development by genetic alteration of donor cells or by tissue culture conditions
11/13/2002	CN1379785A Caspase inhibitors for treatment and prevention of chemotherapy and radiation therapy induced cell death
11/13/2002	CN1379784A Production of polymorphic forms I and II of finasteride by complexation with group I or II metal
11/13/2002	CN1379782A Subunit optimized fusion proteins
11/13/2002	CN1379772A Substituted indoles for modulating NFKB activity
11/13/2002	CN1379763A Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
11/13/2002	CN1379762A Beta substituted metalloprotease inhibitors
11/13/2002	CN1379685A Novel method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and beta integrins
11/13/2002	CN1379684A Treating prostate cancer with anti-ErbB2 antibodies
11/13/2002	CN1379675A 24-hydroxyvitamin D, analogs and use thereof
11/13/2002	CN1379668A 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents
11/13/2002	CN1379666A Non-peptide GnRH agents, methods and intermediates for their preparation

1 ... 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 ... 2211